相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Characterisation of inverse agonism of the orphan-G protein-coupled receptor GPR52 by cannabinoid ligands Cannabidiol and O-1918
Lisa A. Stott et al.
HELIYON (2021)
Discovery of the First Druggable GPR52 Antagonist to Treat Huntington's Disease
Hidetoshi Komatsu
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Selective suppression of polyglutamine-expanded protein by lipid nanoparticle-delivered siRNA targeting CAG expansions in the mouse CNS
Tomoki Hirunagi et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2021)
GPR52 Agonists Attenuate Ropinirole-Induced Preference for Uncertain Outcomes
Brittney Russell et al.
BEHAVIORAL NEUROSCIENCE (2021)
GPR52 Antagonist Reduces Huntingtin Levels and Ameliorates Huntington's Disease-Related Phenotypes
Congcong Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Therapeutic Antisense Targeting of Huntingtin
Anne Smith et al.
DNA AND CELL BIOLOGY (2020)
Structural basis of ligand recognition and self-activation of orphan GPR52
Xi Lin et al.
NATURE (2020)
Gene therapy for neurodegenerative disorders: advances, insights and prospects
Wei Chen et al.
ACTA PHARMACEUTICA SINICA B (2020)
New Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges
Sonia Messina et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Discovery of Potent and Brain-Penetrant GPR52 Agonist that Suppresses Psychostimulant Behavior
Pingyuan Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Investigational Assay for Haplotype Phasing of the Huntingtin Gene
Nenad Svrzikapa et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2020)
Huntington's Disease Clinical Trials Corner: April 2020
Filipe B. Rodrigues et al.
JOURNAL OF HUNTINGTONS DISEASE (2020)
Targeting Huntingtin Expression in Patients with Huntington's Disease
Sarah J. Tabrizi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Emerging therapies in Huntington?s disease
Hassaan Bashir
EXPERT REVIEW OF NEUROTHERAPEUTICS (2019)
Cerebellar modulation of the reward circuitry and social behavior
Flaria Carta et al.
SCIENCE (2019)
Antisense oligonucleotides: the next frontier for treatment of neurological disorders
Carlo Rinaldi et al.
NATURE REVIEWS NEUROLOGY (2018)
Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes
Haikun Song et al.
BRAIN (2018)
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing
Barry Boland et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease
Lauren M. Byrne et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Huntingtin suppression restores cognitive function in a mouse model of Huntington's disease
Amber L. Southwell et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations
Tiago A. Mestre et al.
MOVEMENT DISORDERS CLINICAL PRACTICE (2018)
FTBMT, a Novel and Selective GPR52 Agonist, Demonstrates Antipsychotic-Like and Procognitive Effects in Rodents, Revealing a Potential Therapeutic Agent for Schizophrenia
Keiji Nishiyama et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
Lipid Nanoparticle Systems for Enabling Gene Therapies
Pieter R. Cullis et al.
MOLECULAR THERAPY (2017)
Trends in GPCR drug discovery: new agents, targets and indications
Alexander S. Hauser et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Mutant Huntingtin Disrupts the Nuclear Pore Complex
Jonathan C. Grima et al.
NEURON (2017)
Cellular selectivity of AAV serotypes for gene delivery in neurons and astrocytes by neonatal intracerebroventricular injection
Sean L. Hammond et al.
PLOS ONE (2017)
Juvenile Huntington's Disease: Diagnostic and Treatment Considerations for the Psychiatrist
Joanna Quigley
CURRENT PSYCHIATRY REPORTS (2017)
Genetic deletion of GPR52 enhances the locomotor-stimulating effect of an adenosine A2A receptor antagonist in mice: A potential role of GPR52 in the function of striatopallidal neurons
Keiji Nishiyama et al.
BRAIN RESEARCH (2017)
Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia
Megan S. Keiser et al.
HUMAN MOLECULAR GENETICS (2016)
Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels
Laura Rue et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Benjamin E. Deverman et al.
NATURE BIOTECHNOLOGY (2016)
The Prevalence of Huntington's Disease
Michael D. Rawlins et al.
NEUROEPIDEMIOLOGY (2016)
Ablation of huntingtin in adult neurons is nondeleterious but its depletion in young mice causes acute pancreatitis
Guohao Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Design, Characterization, and Lead Selection of Therapeutic miRNAs Targeting Huntingtin for Development of Gene Therapy for Huntington's Disease
Jana Miniarikova et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2016)
Mapping dopaminergic deficiencies in the substantia nigra/ventral tegmental area in schizophrenia
Matthew W. Rice et al.
BRAIN STRUCTURE & FUNCTION (2016)
Dynamic dual-isotope molecular imaging elucidates principles for optimizing intrathecal drug delivery
Daniel A. Wolf et al.
JCI INSIGHT (2016)
Novel Therapeutic GPCRs for Psychiatric Disorders
Hidetoshi Komatsu
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity
Yuwei Yao et al.
ELIFE (2015)
Huntington disease
Gillian P. Bates et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Personalized gene silencing therapeutics for Huntington disease
C. Kay et al.
CLINICAL GENETICS (2014)
Discovery of the First Potent and Orally Available Agonist of the Orphan G-Protein-Coupled Receptor 52
Masaki Setoh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Diagnostic Criteria for Huntington's Disease Based on Natural History
Ralf Reilmann et al.
MOVEMENT DISORDERS (2014)
Genetic Modifiers of Huntington's Disease
James F. Gusella et al.
MOVEMENT DISORDERS (2014)
Anatomical Transcriptome of G Protein-Coupled Receptors Leads to the Identification of a Novel Therapeutic Candidate GPR52 for Psychiatric Disorders
Hidetoshi Komatsu et al.
PLOS ONE (2014)
Choosing an animal model for the study of Huntington's disease
Mahmoud A. Pouladi et al.
NATURE REVIEWS NEUROSCIENCE (2013)
Analysis of Transduction Efficiency, Tropism and Axonal Transport of AAV Serotypes 1, 2, 5, 6, 8 and 9 in the Mouse Brain
Dominik F. Aschauer et al.
PLOS ONE (2013)
Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease
Kirupa Sathasivam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Antisense Oligonucleotide-Mediated Correction of Transcriptional Dysregulation is Correlated with Behavioral Benefits in the YAC128 Mouse Model of Huntington's Disease
Lisa M. Stanek et al.
JOURNAL OF HUNTINGTONS DISEASE (2013)
Induced Pluripotent Stem Cells from Patients with Huntington's Disease Show CAG-Repeat-Expansion-Associated Phenotypes
CELL STEM CELL (2012)
The incidence and prevalence of Huntington's disease: A systematic review and meta-analysis
Tamara Pringsheim et al.
MOVEMENT DISORDERS (2012)
Sustained Therapeutic Reversal of Huntington's Disease by Transient Repression of Huntingtin Synthesis
Holly B. Kordasiewicz et al.
NEURON (2012)
Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis
Surya A. Reis et al.
HUMAN MOLECULAR GENETICS (2011)
Development of biomarkers for Huntington's disease
David W. Weir et al.
LANCET NEUROLOGY (2011)
Preclinical Safety of RNAi-Mediated HTT Suppression in the Rhesus Macaque as a Potential Therapy for Huntington's Disease
Jodi L. McBride et al.
MOLECULAR THERAPY (2011)
Proteolysis of Mutant Huntingtin Produces an Exon 1 Fragment That Accumulates as an Aggregated Protein in Neuronal Nuclei in Huntington Disease
Christian Landles et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Chiara Zuccato et al.
PHYSIOLOGICAL REVIEWS (2010)
A majority of Huntington's disease patients may be treatable by individualized allele-specific RNA interference
Maria Stella Lombardi et al.
EXPERIMENTAL NEUROLOGY (2009)
Mutant Huntingtin N-terminal Fragments of Specific Size Mediate Aggregation and Toxicity in Neuronal Cells
Tamara Ratovitski et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2009)
AAV9: a potential blood-brain barrier buster
Fredric P. Manfredsson et al.
MOLECULAR THERAPY (2009)
Nonallele-specific Silencing of Mutant and Wild-type Huntingtin Demonstrates Therapeutic Efficacy in Huntington's Disease Mice
Ryan L. Boudreau et al.
MOLECULAR THERAPY (2009)
Anatomical Profiling of G Protein-Coupled Receptor Expression
Jean B. Regard et al.
CELL (2008)
Detection of Huntington's disease decades before diagnosis: the Predict-HD study
J. S. Paulsen et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2008)
AAV vector-mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington's disease
Nicholas R. Franich et al.
MOLECULAR THERAPY (2008)
Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: Implications for the therapeutic development of RNAi
Jodi L. McBride et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Huntingtin has a membrane association signal that can modulate huntingtin aggregation, nuclear entry and toxicity
Randy Singh Atwal et al.
HUMAN MOLECULAR GENETICS (2007)
Therapeutic silencing of mutant huntingtin with siRNA attenuates striatal and cortical neuropathology and behavioral deficits
M. DiFiglia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Targeting the dopamine D2 receptor in schizophrenia
Philip Seeman
EXPERT OPINION ON THERAPEUTIC TARGETS (2006)
Huntingtin-HAP40 complex is a novel Rab5 effector that regulates early endosome motility and is up-regulated in Huntington's disease
A Pal et al.
JOURNAL OF CELL BIOLOGY (2006)
Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease
M Alpay et al.
PSYCHOSOMATICS (2006)
Normal huntingtin function: An alternative approach to Huntington's disease
E Cattaneo et al.
NATURE REVIEWS NEUROSCIENCE (2005)
HD CAG repeat implicates a dominant property of huntingtin in mitochondrial energy metabolism
IS Seong et al.
HUMAN MOLECULAR GENETICS (2005)
RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model
SQ Harper et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin - Implications for nuclear toxicity in Huntington's disease pathogenesis
JA Sayer et al.
NEUROMOLECULAR MEDICINE (2005)
Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease
EJ Slow et al.
HUMAN MOLECULAR GENETICS (2003)
The G protein-coupled receptor repertoires of human and mouse
DK Vassilatis et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Neuroscience - The neurobiology of slow synaptic transmission
P Greengard
SCIENCE (2001)
Inactivation of Hdh in the brain and testis results in progressive neurodegeneration and sterility in mice
I Dragatsis et al.
NATURE GENETICS (2000)
分享论文
